Inhibrx Biosciences Inc (INBX) Stock Price, Quote & News

Company Profile

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lu...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 795 4220

Website: inhibrx.com

Address:

11025 North Torrey Pines Road, Suite 140, La Jolla, United States

Terzman Aug. 19 at 1:03 PM

$INBX 😃

0 · Reply

judgeyoung2 Aug. 14 at 3:53 PM

$INBX they moved it from fourth quarter to third @BullStockpicks1

2 · Reply

Mike22332233 Aug. 12 at 9:19 PM

$SLS MY TOP 10 HOLDINGS … 1 is ready to go WEN is moving -- told you about it long ago & the other day ... still expect $10-$12 offer with board then maybe negotiating it up to $13 ! I uncover Special Situation Stocks & asymmetrical plays … most work out … some don't … the key is proper risk management & diversification … Always remember: this is not financial advice … PLEASE, Do your own DD before buying anything ! I've called My #1 holding, SLS, the best asymmetrical investment I've found in my 43 yrs of investing ... I expect MINIMUM BO of $140 and MAXIMUM BO price of $202 in a Bidding War during Q4! EXPECTED % RETURNS FROM MY AVG BUY PRICES ... 1) SLS 3,400%-4,950% 2) $RYAM 88% 3) $MNRO 27%-57% 4) PRTH 39%-56% 5) GFL 28%-35% 6) $INBX 228%-457% 7) ZIM 36% 8) DDI 32%-74% 9) CRTO 38%-48% 10) $WEN 49%-79% LIKE & FOLLOW if you found these ideas useful !!! FOLLOW me 👉 @Mike22332233 as I posted reports on each

3 · Reply

justiceforb_85 Aug. 11 at 1:15 AM

$INBX first company to show OX40 agonism (106) improved ORR and increased CRs in a randomized trial compared with keytruda monotherapy. Ozekibart (109) is the floor for the company's value. Look forward to the Q4 update in HNSCC.

0 · Reply

chefboobyflay Aug. 11 at 12:45 AM

$INBX

0 · Reply

Mike22332233 Aug. 9 at 12:18 PM

$SLS OK ... # 6 Someone asked for my top 10 Special Situation Stock holdings .... I've called $SLS the best asymmetrical investment I've found in my 43 years of investing ... It's the largest holding, by far, in an over $1.35 mil portfolio ... I expect MINIMUM BO of $140 and MAXIMUM BO price of $202 in a Bidding War during Q4! Now #6 ... $INBX ... The interim Phase 2 data for INBRX-106 + KEYTRUDA combination was outstanding and achieved a cORR of 44.0% vs. 21.4% with KEYTRUDA alone ... Patents on MRK's $34 Bil a yr KEYTRUDA franchise will soon run out, but MRK can salvage that franchise, and re-start that patent clock!! .... $MRK will Buy INBRX-106 from INBX .... I just don't know if it will be for $3.5 B ($240/shr) or $7 B ($480) ... and I don't know if it's in 2 months or 6 months !! ... and you will still own the rest of INBX, which is worth just as much -- INBX has done spinoff deals like this in the past !! FOLLOW me 👉 @Mike22332233 for other HUGE profit stocks

2 · Reply

Terzman Aug. 4 at 1:26 PM

$INBX

0 · Reply

Barrington787 Jul. 28 at 4:37 PM

$INBX what a total turd.

2 · Reply

BullStockpicks1 Jul. 28 at 12:20 PM

$INBX here is my updated analysis, huge opportunity https://x.com/bullstkpicks/status/2082077393825542436?s=46&t=cyjtCnUcMDe5-ZCjxf5y_w

0 · Reply

MBWallingford Jul. 24 at 1:24 PM

$INBX head fake again?

0 · Reply

Inhibrx Reports Second Quarter 2026 Financial Results

Aug 13, 2026, 7:00 AM EDT - 6 days ago

Inhibrx Biosciences Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 6 days ago

Inhibrx Biosciences Earnings release: Q2 2026

Jul 16, 2026, 9:00 AM EDT - 4 weeks ago

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

2026-06-15T13:30:13.000Z - 2 months ago

Inhibrx announces FDA acceptance of BLA for ozekibart

Jun 15, 2026, 9:15 AM EDT - 2 months ago

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

2026-05-15T13:15:11.000Z - 3 months ago

Inhibrx price target raised to $325 from $300 at Stifel

May 14, 2026, 4:02 PM EDT - 3 months ago

Inhibrx Reports First Quarter 2026 Financial Results

May 14, 2026, 7:00 AM EDT - 3 months ago

Inhibrx Biosciences Quarterly report: Q1 2026

2026-05-11T16:20:41.000Z - 3 months ago

Inhibrx’s INBRX-106 shows potential benefit in HNSCC

May 11, 2026, 8:30 AM EDT - 3 months ago

Inhibrx Biosciences Transcript: Study update

May 11, 2026, 8:30 AM EDT - 3 months ago

Inhibrx Biosciences Press release: Study update

May 11, 2026, 8:26 AM EDT - 3 months ago

This Surging Biotech Stock Shrugs Off Positive Cancer Trial Results and Slips. What to Know.

May 11, 2026, 8:00 AM EDT - 3 months ago

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

May 8, 2026, 4:00 PM EDT - 3 months ago

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

2026-04-24T13:35:38.000Z - 4 months ago

Inhibrx initiated with an Outperform at LifeSci Capital

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Inhibrx Biosciences Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Inhibrx Biosciences Proxy statement: Proxy filing

2026-04-22T16:50:17.000Z - 4 months ago

Inhibrx price target raised to $300 from $150 at Stifel

2026-04-22T14:07:06.000Z - 4 months ago

Inhibrx trading halted, volatility trading pause

2026-04-22T14:01:35.000Z - 4 months ago

Inhibrx trading resumes

2026-04-22T12:50:13.000Z - 4 months ago

Inhibrx’s cancer drug drawing interest from Merck, Ono, Reuters says

MRK

2026-04-22T12:49:00.000Z - 4 months ago

Inhibrx up 39% at $117 after report of interest from Merck in cancer assets

Apr 22, 2026, 7:02 AM EDT - 4 months ago

Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say

MRK

Apr 21, 2026, 4:30 PM EDT - 4 months ago

Inhibrx Biosciences Transcript: Study update

Apr 21, 2026, 4:30 PM EDT - 4 months ago

Inhibrx Biosciences Press release: Study update

2026-04-21T20:24:03.000Z - 4 months ago

Inhibrx reports interim data from its Phase 1/2 study evaluating ozekibart

Apr 21, 2026, 4:05 PM EDT - 4 months ago

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

Apr 21, 2026, 7:00 AM EDT - 4 months ago

Inhibrx Biosciences Slides: Investor presentation

Apr 20, 2026, 5:03 PM EDT - 4 months ago

Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

2026-04-07T20:17:46.000Z - 4 months ago

Inhibrx initiated with a Buy at Stifel

Mar 19, 2026, 6:00 PM EDT - 5 months ago

Inhibrx Biosciences Earnings release: Q4 2025

Mar 19, 2026, 6:00 PM EDT - 5 months ago

Inhibrx Biosciences Annual report: Q4 2025

2026-03-19T20:10:58.000Z - 5 months ago

Inhibrx reports Q4 EPS ($2.11) vs. ($3.09) last year

Mar 19, 2026, 4:00 PM EDT - 5 months ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Inhibrx Biosciences Slides: Investor presentation

Mar 2, 2026, 4:00 PM EST - 6 months ago

Inhibrx Announces Participation in Upcoming Scientific Conference

Jan 22, 2026, 10:26 AM EST - 7 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE KOD LITE

2025-12-16T22:10:33.000Z - 8 months ago

Inhibrx provides update on INBRX-106 Phase 2/3 clinical trial

Dec 16, 2025, 5:00 PM EST - 8 months ago

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Nov 14, 2025, 6:00 AM EST - 9 months ago

Inhibrx Reports Third Quarter 2025 Financial Results

Nov 13, 2025, 6:00 PM EST - 9 months ago

Inhibrx Biosciences Quarterly report: Q3 2025

Nov 13, 2025, 6:00 PM EST - 9 months ago

Inhibrx Biosciences Earnings release: Q3 2025

Nov 4, 2025, 4:01 PM EST - 10 months ago

Inhibrx Announces Participation in Upcoming Scientific Conferences

Oct 23, 2025, 6:39 PM EDT - 10 months ago

Inhibrx shares surge after bone cancer drug slows disease progression in trial

Oct 23, 2025, 4:30 PM EDT - 10 months ago

Inhibrx Biosciences Transcript: Study Result

Oct 23, 2025, 4:30 PM EDT - 10 months ago

Inhibrx Biosciences Press release: Study Result

Oct 23, 2025, 4:05 PM EDT - 10 months ago

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Oct 22, 2025, 4:01 PM EDT - 10 months ago

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Aug 13, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 6:00 PM EDT - 1 year ago

Inhibrx Biosciences Quarterly report: Q2 2025

Aug 12, 2025, 6:00 PM EDT - 1 year ago

Inhibrx Biosciences Earnings release: Q2 2025

May 14, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Reports First Quarter 2025 Financial Results

May 14, 2025, 8:00 AM EDT - 1 year ago

Inhibrx Biosciences Quarterly report: Q1 2025

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Inhibrx Biosciences Proxy statement: Proxy filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Inhibrx Biosciences Proxy statement: Proxy filing

Apr 1, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Mar 17, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 16, 2025, 7:00 PM EDT - 1 year ago

Inhibrx Biosciences Earnings release: Q4 2024

Mar 16, 2025, 7:00 PM EDT - 1 year ago

Inhibrx Biosciences Annual report: Q4 2024

Jan 21, 2025, 5:01 PM EST - 1 year ago

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Jan 13, 2025, 4:15 PM EST - 1 year ago

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Nov 14, 2024, 4:24 PM EST - 1 year ago

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 7:00 AM EST - 1 year ago

Inhibrx Biosciences Quarterly report: Q3 2024

Nov 4, 2024, 4:00 PM EST - 1 year ago

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Aug 13, 2024, 6:54 PM EDT - 2 years ago

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Quarterly report: Q2 2024

Jun 11, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Registration statement: Registration filing

May 24, 2024, 4:00 PM EDT - 2 years ago

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

May 21, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

May 17, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

May 10, 2024, 6:36 PM EDT - 2 years ago

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

May 9, 2024, 3:36 PM EDT - 2 years ago

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

SNY

May 8, 2024, 4:37 PM EDT - 2 years ago

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Feb 29, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Feb 28, 2024, 9:15 AM EST - 2 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Feb 28, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Annual report: Q4 2023

Feb 6, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Jan 23, 2024, 11:45 AM EST - 2 years ago

Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline

SNY

Jan 23, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Jan 23, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Jan 23, 2024, 5:39 AM EST - 2 years ago

Sanofi to Buy Rare-Disease Assets From Inhibrx

SNY

Jan 23, 2024, 1:32 AM EST - 2 years ago

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

SNY

Jan 23, 2024, 1:30 AM EST - 2 years ago

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

SNY

Jan 23, 2024, 1:00 AM EST - 2 years ago

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

SNY

Nov 9, 2023, 4:00 PM EST - 3 years ago

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 2, 2023, 9:15 AM EDT - 3 years ago

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Sep 19, 2023, 4:00 PM EDT - 3 years ago

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

Sep 1, 2023, 4:26 PM EDT - 3 years ago

Andreas Halvorsen's Firm Ups Inhibrx Stake

Aug 29, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Announces $200 Million Private Placement Financing

Aug 7, 2023, 4:00 PM EDT - 3 years ago

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

May 30, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

May 8, 2023, 4:05 PM EDT - 3 years ago

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Apr 26, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

Apr 13, 2023, 8:00 AM EDT - 3 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Apr 13, 2023, 8:00 AM EDT - 3 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Mar 6, 2023, 4:05 PM EST - 3 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Terzman Aug. 19 at 1:03 PM

$INBX 😃

0 · Reply

judgeyoung2 Aug. 14 at 3:53 PM

$INBX they moved it from fourth quarter to third @BullStockpicks1

2 · Reply

Mike22332233 Aug. 12 at 9:19 PM

3 · Reply

justiceforb_85 Aug. 11 at 1:15 AM

0 · Reply

chefboobyflay Aug. 11 at 12:45 AM

$INBX

0 · Reply

Mike22332233 Aug. 9 at 12:18 PM

2 · Reply

Terzman Aug. 4 at 1:26 PM

$INBX

0 · Reply

Barrington787 Jul. 28 at 4:37 PM

$INBX what a total turd.

2 · Reply

BullStockpicks1 Jul. 28 at 12:20 PM

$INBX here is my updated analysis, huge opportunity https://x.com/bullstkpicks/status/2082077393825542436?s=46&t=cyjtCnUcMDe5-ZCjxf5y_w

0 · Reply

MBWallingford Jul. 24 at 1:24 PM

$INBX head fake again?

0 · Reply

Terzman Jul. 23 at 12:24 PM

$INBX new loan facility is inbx way of giving big pharma 🖕🏾 for any low ball effort to play ball .. if you wanna play with it ya gotta pay for it .. load up

0 · Reply

justiceforb_85 Jul. 23 at 2:05 AM

$INBX remains significantly undervalued. Look forward to INBRX-106 updates on PFS in HNSCC.

0 · Reply

MBWallingford Jul. 15 at 1:27 PM

$INBX 20 shares? Some kind of head fake.

0 · Reply

Innerchild Jul. 10 at 8:29 AM

$MTEN Stop buying Mten this shit , go buy rather $JLHL $OMEX $CRMT $INBX Go long for tickers that actually pay, but be careful with JLHL it’s a Chineese / Asian, shit could go sideways, just like GDC.

0 · Reply

MBWallingford Jul. 9 at 11:12 PM

$INBX the stock is now acting like something is brewing. A bit more volume would confirm.

0 · Reply

Stacks_Edwards Jul. 9 at 3:46 PM

$INBX Let’s get going here baby!!

0 · Reply

Mike22332233 Jul. 9 at 3:14 PM

$INBX I Believe $MRK has a strong interest to buy out BOTH OF THESE — $SLS and $INBX — my number one and number two top holdings !!! … Which will go first??? Thoughts … LIKE & FOLLOW @mike22332233

1 · Reply

Doozio Jul. 8 at 12:21 AM

$INBX again this 🐑 week ENTA 🐒🍌🧠⏰♾️?

0 · Reply

Mike22332233 Jul. 7 at 6:43 PM

$SLS Will $MRK do a BO of $SLS or of $INBX FIRST?? … Will they do both??? … I am covered either way … LIKE & FOLLOW me 👉 @Mike22332233 for SLS insight you will find nowhere else

0 · Reply

Innerchild Jul. 7 at 6:20 PM

$MTEN will Soon 🚀🚀🚀 $VRXA $PHOE $INBX all going down now

0 · Reply

Layne_Thomas_Staley Jul. 7 at 6:01 PM

$INBX $

0 · Reply

justiceforb_85 Jul. 6 at 11:04 PM

$INBX look forward to PFS update for 106 in the fall.

0 · Reply

Market Cap	1.35B
Revenue (ttm)	1.30M
Net Income (ttm)	-140.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-10,773.85%
Debt to Equity Ratio	-3.33

Volume	311,200
Avg Vol	291,698
Day's Range	N/A - N/A
Shares Out	14.67M
Stochastic %K	69%
Beta	3.51
Analysts	Sell
Price Target	$277.50